

Estimated annual cost: \$7,920,000, includes \$91,300 annualized capital or O&M costs.

Changes in estimates: There is no change in burden from the previous ICR.

(22) *Docket ID Number:* EPA–HQ–OECA–2013–0323; NESHAP for Area Sources: Electric Arc Furnace Steelmaking Facilities (40 CFR part 63, subpart YYYYY) (Renewal); EPA ICR Number 2277.06; OMB Control Number 2060–0608; Expiration date August 31, 2021.

Respondents: Electric Arc Furnace (EAF) Steelmaking facilities that are area sources of HAP emissions.

Respondent's obligation to respond: Mandatory (40 CFR part 63, subpart YYYYY).

Estimated number of respondents: 91.

Frequency of response: Initially, occasionally, and semiannually.

Estimated annual burden: 4,450 hours.

Estimated annual cost: \$467,000, includes \$0 annualized capital or O&M costs.

Changes in estimates: There is no change in burden from the previous ICR.

(23) *Docket ID Number:* EPA–HQ–OECA–2014–0027; NSPS for Bulk Gasoline Terminals (40 CFR part 60, subpart XX) (Renewal); EPA ICR Number 0664.13; OMB Control Number 2060–0006; Expiration date September 30, 2021.

Respondents: Bulk gasoline terminal facilities.

Respondent's obligation to respond: Mandatory (40 CFR part 60, subpart XX).

Estimated number of respondents: 40.

Frequency of response: Initially.

Estimated annual burden: 13,200 hours.

Estimated annual cost: \$1,390,000, includes \$0 annualized capital or O&M costs.

Changes in estimates: There is no change in burden from the previous ICR.

(24) *Docket ID Number:* EPA–HQ–OECA–2014–0099; NESHAP for Ferroalloys Production Area Sources (40 CFR part 63, subpart YYYYYY) (Renewal); EPA ICR Number 2303.06; OMB Control Number 2060–0625; Expiration date September 30, 2021.

Respondents: Ferroalloys production facilities that are area sources of HAP emissions.

Respondent's obligation to respond: Mandatory (40 CFR part 63, subpart YYYYYY).

Estimated number of respondents: 10.

Frequency of response: Initially and annually.

Estimated annual burden: 391 hours.

Estimated annual cost: \$41,100, includes \$0 annualized capital or O&M costs.

Changes in estimates: There is no change in burden from the previous ICR.

Martha Segall,

Acting Director, Monitoring, Assistance and Media Programs Division, Office of Compliance.

[FR Doc. 2020–10097 Filed 5–11–20; 8:45 am]

BILLING CODE 6560–50–P

EXPORT-IMPORT BANK OF THE UNITED STATES

Sunshine Act Meeting; Notice of an Open Meeting of the Board of Directors of the Export-Import Bank of the United States

TIME AND DATE: Thursday, May 21, 2020 at 10:00 a.m.

PLACE: The meeting will be held via Teleconference.

STATUS: The meeting will be open to public observation by teleconference.

MATTER TO BE CONSIDERED:

- Item No. 1 Small Business Update.
- Item No. 2 Additionality and Economic Impact Reforms.

CONTACT PERSON FOR MORE INFORMATION:

Members of the public who wish to attend the meeting should email Joyce Stone, Office of the General Counsel, 811 Vermont Avenue NW, Washington, DC 20571 (joyce.stone@exim.gov) by close of business Tuesday, May 19, 2020. Individuals will be given call-in information upon notice of attendance to EXIM.

Joyce Stone,

Assistant Corporate Secretary.

[FR Doc. 2020–10220 Filed 5–8–20; 11:15 am]

BILLING CODE 6690–01–P

FEDERAL TRADE COMMISSION

[File No. 191 0169]

AbbVie Inc. and Allergan plc; Analysis of Consent Order To Aid Public Comment

AGENCY: Federal Trade Commission.

ACTION: Proposed consent agreement; request for comment.

SUMMARY: The consent agreement in this matter settles alleged violations of federal law prohibiting unfair methods of competition. The attached Analysis to Aid Public Comment describes both the allegations in the complaint and the terms of the consent order—embodied in the consent agreement—that would settle these allegations.

DATES: Comments must be received on or before June 11, 2020.

ADDRESSES: Interested parties may file comments online or on paper, by following the instructions in the Request for Comment part of the **SUPPLEMENTARY INFORMATION** section below. Please write: “AbbVie and Allergan; File No. 191 0169” on your comment, and file your comment online at <https://www.regulations.gov> by following the instructions on the web-based form. If you prefer to file your comment on paper, please mail your comment to the following address: Federal Trade Commission, Office of the Secretary, 600 Pennsylvania Avenue NW, Suite CC–5610 (Annex D), Washington, DC 20580; or deliver your comment to the following address: Federal Trade Commission, Office of the Secretary, Constitution Center, 400 7th Street SW, 5th Floor, Suite 5610 (Annex D), Washington, DC 20024.

FOR FURTHER INFORMATION CONTACT: Kari Wallace (202–326–3085), Bureau of Competition, Federal Trade Commission, 600 Pennsylvania Avenue NW, Washington, DC 20580.

SUPPLEMENTARY INFORMATION: Pursuant to Section 6(f) of the Federal Trade Commission Act, 15 U.S.C. 46(f), and FTC Rule 2.34, 16 CFR 2.34, notice is hereby given that the above-captioned consent agreement containing a consent order to cease and desist, having been filed with and accepted, subject to final approval, by the Commission, has been placed on the public record for a period of thirty (30) days. The following Analysis of Agreement Containing Consent Orders to Aid Public Comment describes the terms of the consent agreement and the allegations in the complaint. An electronic copy of the full text of the consent agreement package can be obtained from the FTC website (for May 5, 2020), at this web address: <https://www.ftc.gov/news-events/commission-actions>.

You can file a comment online or on paper. For the Commission to consider your comment, we must receive it on or before June 11, 2020. Write “AbbVie and Allergan; File No. 191 0169” on your comment. Your comment—including your name and your state—will be placed on the public record of this proceeding, including, to the extent practicable, on the <https://www.regulations.gov> website.

Due to the public health emergency in response to the COVID–19 outbreak and the agency’s heightened security screening, postal mail addressed to the Commission will be subject to delay. We strongly encourage you to submit your